NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222) [ID468]

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator
Email: TACommA@nice.org.uk **Fax**: +44 (0)20 xxxx xxxx
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by **Dr Patrick Cardogan from RCP on behalf of NCRI/RCP/RCR/ACP/JCCO** and consequently I will not be submitting a personal statement.

Name: Prof Ledermann

Signed: [redacted]

Date: 27 July 2013